TY - JOUR
T1 - Netarsudil as a Predictor of Response for MicroPulse Transscleral Laser Therapy
T2 - A Pilot Study
AU - Xu, Haochen
AU - Lee, Dayeong
AU - Cho, Junsang
AU - Voss, Jackson
AU - McDaniel, Lindsey
AU - An, Jella Angela
N1 - Funding Information:
This study includes human subjects. University of Missouri Institutional Review Board approval was obtained (IRB #2018280) and a waiver was granted for this retrospective analysis of electronic health records. The study protocol adhered to the tenets of the Declaration of Helsinki. Clinical data were retrieved from the electronic medical records and stored in compliance with the Health Insurance Portability and Accountability Act. All information presented in this study is HIPAA compliant. No funding was provided for this study. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties at the University of Missouri School of Medicine. No additional funding was provided.
Publisher Copyright:
© 2022 American Academy of Ophthalmology
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Purpose: To investigate the role of netarsudil as an outcome predictor of MicroPulse transscleral laser therapy (MPTLT). Design: Retrospective comparative study. Subjects: Forty-seven eyes in 33 adult patients with glaucoma with a minimum of 1 month of follow-up after netarsudil treatment and 3 months of follow-up after MPTLT were included. Eyes receiving intraocular pressure (IOP)–lowering procedures in the interim were excluded. Intervention: Ophthalmic eyedrops of netarsudil at 0.02%, followed by MPTLT treatment. Main Outcome Measures: Correlation of success between netarsudil and MPTLT. Netarsudil success was defined as an IOP reduction ≥ 20% from baseline, whereas MPTLT success was defined as an IOP reduction ≥ 20% without additional IOP-lowering medications. Secondary outcomes included success rates, mean IOP reduction, adverse effects after each treatment, and netarsudil discontinuation rate. Results: We found a positive correlation between the netarsudil response and the subsequent MPTLT response (odds ratio, 3.73; 95% confidence interval, 1.05–13.24; P = 0.041). Among netarsudil responders, 73.7% (14/19) of eyes subsequently responded to MPTLT, whereas among netarsudil nonresponders, 42.8% (12/28) of eyes subsequently responded to MPTLT (P = 0.037). From netarsudil, 44.4% of eyes were successful; from MPTLT, 55.3% of eyes were successful. The mean IOP reductions were 2.83 ± 5.74 mmHg from netarsudil and 3.15 ± 6.43 mmHg from MPTLT. Overall, the rate of netarsudil discontinuation was 55.3%. The most common reasons for netarsudil discontinuation were adverse effects (48.9%), followed by high cost (19.1%). The most common adverse effects to netarsudil were conjunctival hyperemia (48.9%) and blurred vision (8.5%). There were no adverse events reported after MPTLT. After MPTLT, 29.8% of eyes required additional IOP-lowering procedures. Conclusions: The netarsudil response may serve as a predictive marker of the MPTLT response, with over 70% of netarsudil responders subsequently responding favorably to MPTLT in this study.
AB - Purpose: To investigate the role of netarsudil as an outcome predictor of MicroPulse transscleral laser therapy (MPTLT). Design: Retrospective comparative study. Subjects: Forty-seven eyes in 33 adult patients with glaucoma with a minimum of 1 month of follow-up after netarsudil treatment and 3 months of follow-up after MPTLT were included. Eyes receiving intraocular pressure (IOP)–lowering procedures in the interim were excluded. Intervention: Ophthalmic eyedrops of netarsudil at 0.02%, followed by MPTLT treatment. Main Outcome Measures: Correlation of success between netarsudil and MPTLT. Netarsudil success was defined as an IOP reduction ≥ 20% from baseline, whereas MPTLT success was defined as an IOP reduction ≥ 20% without additional IOP-lowering medications. Secondary outcomes included success rates, mean IOP reduction, adverse effects after each treatment, and netarsudil discontinuation rate. Results: We found a positive correlation between the netarsudil response and the subsequent MPTLT response (odds ratio, 3.73; 95% confidence interval, 1.05–13.24; P = 0.041). Among netarsudil responders, 73.7% (14/19) of eyes subsequently responded to MPTLT, whereas among netarsudil nonresponders, 42.8% (12/28) of eyes subsequently responded to MPTLT (P = 0.037). From netarsudil, 44.4% of eyes were successful; from MPTLT, 55.3% of eyes were successful. The mean IOP reductions were 2.83 ± 5.74 mmHg from netarsudil and 3.15 ± 6.43 mmHg from MPTLT. Overall, the rate of netarsudil discontinuation was 55.3%. The most common reasons for netarsudil discontinuation were adverse effects (48.9%), followed by high cost (19.1%). The most common adverse effects to netarsudil were conjunctival hyperemia (48.9%) and blurred vision (8.5%). There were no adverse events reported after MPTLT. After MPTLT, 29.8% of eyes required additional IOP-lowering procedures. Conclusions: The netarsudil response may serve as a predictive marker of the MPTLT response, with over 70% of netarsudil responders subsequently responding favorably to MPTLT in this study.
KW - MicroPulse laser
KW - Netarsudil
KW - Open-angle glaucoma
KW - Rho kinase inhibitor
UR - https://www.scopus.com/pages/publications/85134853761
UR - https://www.scopus.com/pages/publications/85134853761#tab=citedBy
U2 - 10.1016/j.ogla.2022.06.005
DO - 10.1016/j.ogla.2022.06.005
M3 - Article
C2 - 35714908
AN - SCOPUS:85134853761
SN - 2589-4196
VL - 5
SP - 658
EP - 662
JO - Ophthalmology. Glaucoma
JF - Ophthalmology. Glaucoma
IS - 6
ER -